Quantcast

Latest early-stage breast cancer Stories

2010-03-25 08:15:00

REDWOOD CITY, Calif. and BARCELONA, March 25 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company has entered into an exclusive agreement with Palex Medical S.A., one of Europe's leading distributors of medical device and diagnostic services to hospitals, to distribute its Oncotype DX® breast cancer test in Spain and Portugal. The distribution agreement, announced in conjunction with positive data presented today at the 7th...

2010-03-09 16:51:00

PLEASANT HILL, Calif., March 9 /PRNewswire/ -- Advances in the world of radiation therapy have led to the development of a new procedure for the treatment of early stage breast cancer, non-melanoma skin cancers, and some gynecologic cancers. Diablo Valley Oncology/Hematology Medical Group at the California Cancer and Research Institute is pleased to announce that they recently received state approval to be the only facility in Northern California to offer a new breakthrough radiation...

2010-03-08 15:34:00

REDWOOD CITY, Calif., March 8 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of positive results from a large international study which demonstrated that the Oncotype DX® breast cancer Recurrence Score® (RS) result is a significant independent predictor of distant recurrence in both node-negative and node-positive, hormone receptor-positive, postmenopausal breast cancer patients who are treated with either...

2010-01-12 07:00:00

REDWOOD CITY, Calif., Jan. 12 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of a prospective, multi-center, study that showed the Oncotype DX® breast cancer test Recurrence Score® had a significant impact on breast cancer treatment decisions for early-stage breast cancer patients while increasing patient satisfaction and physician confidence in those decisions. The study found that knowledge of a patient's...

2009-12-15 07:00:00

REDWOOD CITY, Calif., Dec. 15 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from five new studies on its Oncotype DX® breast cancer test, a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for patients with early-stage breast cancer. These data were presented at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held December 9 - 13, 2009,...

2009-12-11 07:00:00

SAN ANTONIO, Dec. 11 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from a clinical survey evaluating the impact of the Oncotype DX® Recurrence Score® result on physicians' adjuvant treatment recommendations for patients with node-positive, hormone receptor-positive breast cancer. The findings, presented as a poster at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium (Abstract # 2031), demonstrated...

2009-12-04 07:00:00

REDWOOD CITY, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from five studies at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), taking place December 9-13, 2009, at the Henry B. Gonzalez Convention Center. Four of the studies analyze Oncotype DX®, the company's multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit as...

2009-11-09 15:01:00

BEDFORD, Mass., Nov. 9 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced its results for the fourth quarter and fiscal year ended September 26, 2009. In addition, Hologic today announced the Board of Directors has promoted Robert Cascella to Chief Executive Officer effective...

2009-11-03 09:50:22

Large study finds subset of women that may need additional therapy Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center. The findings, published Nov. 2 online in the Journal of Clinical Oncology, is the first large study to...

2009-11-02 07:00:00

CHICAGO, Nov. 2 /PRNewswire/ -- Xoft, Inc., developer of the Axxent(®) Electronic Brachytherapy, eBx(TM) System, which delivers non-radioactive, electronic therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue, will showcase its growing suite of oncology treatment technologies here at the 51st American Society for Radiology and Oncology (ASTRO) Meeting, November 1-5. Available for treatment of early stage breast cancer, endometrial...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'